Related Experiment Video

Updated: Jul 26, 2026

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
14:24

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

11.7K

Programmatic approach to patients with advanced ischemic cardiomyopathy: Integrating microaxial support into

Jean-Luc A Maigrot1, Aaron J Weiss1, Michael Z Y Tong1

  • 1Department of Thoracic and Cardiovascular Surgery, Kaufman Center for Heart Failure and Recovery, Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio, USA.

Artificial Organs
|November 28, 2023
PubMed

Insights

Managing advanced ischemic cardiomyopathy requires careful risk assessment for optimal treatment. This review details identifying high-risk patients and strategies for personalized therapy to improve outcomes.

Area of Science:

  • Cardiology
  • Heart Failure Research
  • Clinical Medicine

Background:

  • Advanced ischemic cardiomyopathy presents with varying left ventricular dysfunction severity.
  • Treatment decisions are complex, involving medical therapy, revascularization, mechanical support, and transplantation.
  • Suboptimal outcomes can result from misjudging patient risk and selecting inappropriate therapies.

Purpose of the Study:

  • To outline a programmatic approach for evaluating and optimizing high-risk patients with ischemic cardiomyopathy.
  • To present strategies for therapeutic decision-making to enhance patient outcomes.
  • To identify key factors in managing complex cardiac conditions.

Main Methods:

  • Review of current treatment pathways for ischemic cardiomyopathy.
  • Discussion of patient identification and risk stratification protocols.
  • Analysis of decision-making strategies for perioperative optimization.

Main Results:

  • High-risk patients require tailored management plans.
  • A structured evaluation and optimization process is crucial.
  • Personalized therapeutic strategies improve short- and long-term results.

Conclusions:

  • Effective management of ischemic cardiomyopathy hinges on accurate risk assessment and personalized treatment.
  • Programmatic approaches enhance patient care and outcomes.
  • Optimizing therapeutic decisions is key to improving the prognosis for patients with advanced heart conditions.

Keywords:
advanced heart failure therapyadvanced ischemic cardiomyopathyhigh-risk CABGtemporary mechanical circulatory support

More Related Videos

Ultrasound-Guided Induced Pluripotent Stem Cell-Derived Cardiomyocyte Implantation in Myocardial Infarcted Mice08:03

Ultrasound-Guided Induced Pluripotent Stem Cell-Derived Cardiomyocyte Implantation in Myocardial Infarcted Mice

Published on: March 30, 2022

1.6K
Author Spotlight: Enhancing Coronary Artery Revascularization05:25

Author Spotlight: Enhancing Coronary Artery Revascularization

Published on: September 15, 2023

738

Related Concept Videos

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...